BeyondSpring Inc.
BYSI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BYSI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BYSI
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing its lead asset Plinabulin, a small-molecule agent being studied for chemotherapy-induced neutropenia (CIN) prevention and as a direct anticancer therapy in non-small cell lung cancer (NSCLC). The company has no approved products, no revenue, and a history of net losses, with its near-term viability dependent on successful clinical outcomes and additional financing.
Key risk: Cash runway risk
BioSniper Score
Based on 5 of 6 signals
Market Cap
$27.4M
Cash Runway
5.8 moLead Asset
Plinabulin (Phase 3)
Next Catalyst
Phase3_Topline · Dec 1, 2029Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 2 clinical trials · 1 catalyst for BeyondSpring Inc..
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing its lead asset Plinabulin, a small-molecule agent being studied for chemotherapy-induced neutropenia (CIN) prevention and as a direct anticancer therapy in non-small cell lung cancer (NSCLC). The company has no approved products, no revenue, and a history of net losses, with its near-term viability dependent on successful clinical outcomes and additional financing.
- Lead product candidate Plinabulin is being evaluated in a Phase 3 trial for NSCLC in combination with docetaxel, with topline data expected in December 2025 [sec_mda · as of 2026-08-14].
- As of June 30, 2026, the company had cash and equivalents of $2.7 million, zero revenue, a net loss of $0.8 million for the quarter, and negative shareholders' equity of -$32.2 million [sec].
- Accumulated deficit reached $411.4 million as of June 30, 2026, reflecting sustained R&D and administrative expenses without product revenue [sec_mda · as of 2026-08-14].
- The company has not yet demonstrated the ability to complete large-scale pivotal trials, obtain regulatory approvals, or commercialize a drug [sec · filed 2023-04-18].
- BeyondSpring's pipeline is heavily dependent on Plinabulin; other product candidates remain in preclinical or early stages and have not entered clinical trials [sec · filed 2023-04-18].
What works
- Plinabulin has a defined regulatory path with a Phase 3 trial in NSCLC that is fully enrolled and topline data expected in December 2025, providing a potential near-term catalyst [sec_mda · as of 2026-08-14].
- The company has invested significant resources in Plinabulin across multiple indications, including CIN prevention and direct anticancer therapy, which could address large markets if approved [sec · filed 2023-04-18].
- BeyondSpring has established intellectual property protection for Plinabulin, which may provide competitive advantages if the drug is successfully developed [sec · filed 2023-04-18].
What to weigh
- The company has incurred net losses every period since inception and expects to continue losing money for the foreseeable future, with an accumulated deficit of $411.4 million as of June 30, 2026 [sec_mda · as of 2026-08-14].
- Cash and equivalents of only $2.7 million as of June 30, 2026, raise substantial doubt about the company's ability to fund operations without additional financing [sec].
- BeyondSpring is entirely dependent on the success of Plinabulin; if it fails to gain approval, the company has no other late-stage candidates to fall back on [sec · filed 2023-04-18].
- The company has no approved products, no revenue from product sales, and has not yet demonstrated the ability to complete large-scale pivotal trials or obtain regulatory approvals [sec · filed 2023-04-18].
From the filings
Quoted directly from source documents.
The company has incurred net losses in each period since inception and expects to continue incurring losses.
“We have incurred net losses in each period since our inception and anticipate that we will continue to incur net losses for the foreseeable future.”
SEC filings · April 29, 2024
The company has not yet demonstrated the ability to complete large-scale pivotal trials or obtain regulatory approvals.
“We have not yet demonstrated the ability to successfully complete large-scale, pivotal clinical trials, obtain regulatory approvals, manufacture a commercial scale drug, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessa”
SEC filings · April 18, 2023
Accumulated deficit reached $411.4 million as of June 30, 2026.
“As of December 31, 2025 and June 30, 2026, we had an accumulated deficit of $408.4 million and $411.4 million, respectively.”
SEC MD&A · August 14, 2026
Catalyst timeline
- 2025-12-01 · Phase3_Topline · docetaxel — Phase 3 Topline: A Global, Multicenter, Randomized, Double-blinded, Phase 3 Study of Docetaxel + Plinabulin Compared — Topline results from the pivotal Phase 3 trial of Plinabulin in combination with docetaxel for NSCLC will be a key value inflection point.
Risks & what to watch (4)›
Key risks
- Cash runway risk — Only $2.7M cash as of June 30, 2026, insufficient to fund operations without additional financing [sec].
- Single-asset dependency — Pipeline is almost entirely dependent on Plinabulin; failure would leave no late-stage candidates [sec · filed 2023-04-18].
- No revenue or profitability — No approved products, zero product revenue, and accumulated deficit of $411.4M [sec_mda · as of 2026-08-14].
- Clinical and regulatory uncertainty — Has not yet completed a large-scale pivotal trial or obtained any regulatory approval [sec · filed 2023-04-18].
What to watch
- Phase 3 topline data for Plinabulin in NSCLC expected in December 2025 [sec_mda · as of 2026-08-14].
- Ability to secure additional financing given low cash reserves [sec].
- Regulatory interactions with FDA, NMPA, or EMA regarding Plinabulin for CIN or NSCLC [sec · filed 2024-04-29].
- Progress of preclinical or early-stage pipeline candidates beyond Plinabulin [sec · filed 2023-04-18].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run BeyondSpring Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BeyondSpring Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
5.8 months
OCF -$4M · Net income -$849K
Lead: Phase 3
1 candidate
1 upcoming, next in ~1189d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
18
Total value held
$4.5M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,215,868 | $2.0M |
| blackrock, inc. | 649,462 | $1.1M |
| geode capital management, llc | 375,371 | $616K |
| state street corp | 231,120 | $379K |
| vanguard fiduciary trust co | 179,925 | $295K |
| northern trust corp | 69,268 | $114K |
| susquehanna international group, llp | 22,300 | $37K |
| renaissance technologies llc | 11,100 | $18K |
| morgan stanley | 4,570 | $7K |
| national bank of canada /fi/ | 2,875 | $5K |
Showing top 10 of 18 institutional holders of BeyondSpring Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 6.4%
- Days to cover
- 224.7
- Shares short
- 2,188,849
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BYSI short interestFrequently asked questions
What is the AI investment thesis for BeyondSpring Inc.?
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing its lead asset Plinabulin, a small-molecule agent being studied for chemotherapy-induced neutropenia (CIN) prevention and as a direct anticancer therapy in non-small cell lung cancer (NSCLC). The company has no approved products, no revenue, and a history of net losses, with its near-term viability dependent on successful clinical outcomes and additional financing.
What is BeyondSpring Inc.'s lead drug candidate?
BeyondSpring Inc.'s most advanced tracked candidate is Plinabulin (Phase 3) for Non-Small Cell Lung Cancer.
What is BeyondSpring Inc.'s next catalyst?
BeyondSpring Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Global, Multicenter, Randomized, Double-blinded, Phase 3 Study of Docetaxel + Plinabulin Compared " — expected December 1, 2029.
Who is the CEO of BeyondSpring Inc.?
Mr. Min Qiu is the chief executive officer of BeyondSpring Inc. (BYSI).
Where is BeyondSpring Inc. headquartered?
BeyondSpring Inc. (BYSI) is headquartered in Florham Park, NJ, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.